Spero

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Spero Therapeutics, Inc. (SPRO) Investors

Retrieved on: 
Monday, June 6, 2022
Legal, Professional Services, New Drug Application, Time, Company, HBR, Food, Court, News, Workforce, Therapy, FDA, Defendant, Review, Spero, NASDAQ, Twitter, Law, Tebipenem, Urinary tract infection, Lists of schools in England, NDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Person, Suite, Pharmaceutical industry

The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired Spero Therapeutics, Inc. (Spero or the Company) (NASDAQ: SPRO ) securities between October 28, 2021 and May 2, 2022, inclusive (the Class Period).

Key Points: 
  • The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired Spero Therapeutics, Inc. (Spero or the Company) (NASDAQ: SPRO ) securities between October 28, 2021 and May 2, 2022, inclusive (the Class Period).
  • Spero investors have until July 25, 2022 to file a lead plaintiff motion.
  • On this news, Speros stock fell $1.59, or 18.27%, to close at $7.11 per share on April 1, 2022.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Spero Therapeutics, Inc. (SPRO) Investors

Retrieved on: 
Monday, June 6, 2022
Legal, Professional Services, New Drug Application, Company, HBR, Food, News, Telephone, Workforce, Therapy, FDA, Defendant, Review, Spero, NASDAQ, Law, Tebipenem, Urinary tract infection, Lists of schools in England, NDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Suite, Security (finance), Pharmaceutical industry

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Spero Therapeutics, Inc. (Spero or the Company) (NASDAQ: SPRO ) securities between October 28, 2021 and May 2, 2022, inclusive (the Class Period).

Key Points: 
  • Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Spero Therapeutics, Inc. (Spero or the Company) (NASDAQ: SPRO ) securities between October 28, 2021 and May 2, 2022, inclusive (the Class Period).
  • Spero investors have until July 25, 2022 to file a lead plaintiff motion.
  • Investors suffering losses on their Spero investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to [email protected] .
  • On this news, Speros stock fell $1.59, or 18.27%, to close at $7.11 per share on April 1, 2022.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Spero Therapeutics, Inc. (SPRO) on Behalf of Investors

Retrieved on: 
Friday, June 3, 2022
Legal, Professional Services, New Drug Application, DOJ, Company, Insurance, Program, HBR, Food, Financial Times, News, Press, Real estate investment trust, Workforce, The Wall Street Journal, FDA, Publication, Person, Review, Spero, Associated Press, Bloomberg Businessweek, SCAS, GPM, NASDAQ, SEC, Industry, Urinary tract infection, NDA, Information technology, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, LLP, Medical device, Pharmaceutical industry, Reuters, Forbes

Glancy Prongay & Murray LLP (GPM), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Spero Therapeutics, Inc. (Spero or the Company) (NASDAQ: SPRO ) investors concerning the Companys possible violations of the federal securities laws.

Key Points: 
  • Glancy Prongay & Murray LLP (GPM), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Spero Therapeutics, Inc. (Spero or the Company) (NASDAQ: SPRO ) investors concerning the Companys possible violations of the federal securities laws.
  • On this news, Speros stock fell $1.59, or 18.27%, to close at $7.11 per share on April 1, 2022.
  • Glancy Prongay & Murray LLP is a premier law firm representing investors and consumers in securities litigation and other complex class action litigation.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Bronstein, Gewirtz & Grossman, LLC Notifies Spero Therapeutics, Inc. (SPRO) Shareholders of Class Action and Encourages Investors to Contact the Firm

Retrieved on: 
Friday, June 3, 2022
Legal, Professional Services, LLC, Complaint, Court, Workforce, FDA, Review, NASDAQ, Tebipenem, Lists of schools in England, NDA, Person, Security (finance), Spero

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws.

Key Points: 
  • This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws.
  • The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Companys business, operations, and prospects.
  • or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484.
  • Bronstein, Gewirtz & Grossman, LLC represents investors in securities fraud class actions and shareholder derivative suits.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Spero Therapeutics, Inc. (SPRO) on Behalf of Investors

Retrieved on: 
Friday, June 3, 2022
Legal, Professional Services, New Drug Application, Company, HBR, Food, News, Telephone, Workforce, FDA, Review, Spero, NASDAQ, Urinary tract infection, NDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Suite, Pharmaceutical industry

Law Offices of Howard G. Smith announces an investigation on behalf of Spero Therapeutics, Inc. (Spero or the Company) (NASDAQ: SPRO ) investors concerning the Companys possible violations of federal securities laws.

Key Points: 
  • Law Offices of Howard G. Smith announces an investigation on behalf of Spero Therapeutics, Inc. (Spero or the Company) (NASDAQ: SPRO ) investors concerning the Companys possible violations of federal securities laws.
  • On this news, Speros stock fell $1.59, or 18.27%, to close at $7.11 per share on April 1, 2022.
  • On this news, Speros stock fell $3.25, or 63.65%, to close at $1.85 per share on May 3, 2022, thereby injuring investors further.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

The Law Offices of Frank R. Cruz Announces Investigation of Spero Therapeutics, Inc. (SPRO) on Behalf of Investors

Retrieved on: 
Thursday, June 2, 2022
Legal, Professional Services, New Drug Application, Company, HBR, Food, News, Workforce, Therapy, FDA, Review, Spero, NASDAQ, Twitter, Law, Urinary tract infection, NDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Suite, Pharmaceutical industry

The Law Offices of Frank R. Cruz announces an investigation of Spero Therapeutics, Inc. (Spero or the Company) (NASDAQ: SPRO ) on behalf of investors concerning the Companys possible violations of federal securities laws.

Key Points: 
  • The Law Offices of Frank R. Cruz announces an investigation of Spero Therapeutics, Inc. (Spero or the Company) (NASDAQ: SPRO ) on behalf of investors concerning the Companys possible violations of federal securities laws.
  • On this news, Speros stock fell $1.59, or 18.27%, to close at $7.11 per share on April 1, 2022.
  • On this news, Speros stock fell $3.25, or 63.65%, to close at $1.85 per share on May 3, 2022, thereby injuring investors further.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

SPERO ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Spero Therapeutics, Inc. and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, June 2, 2022
Legal, Professional Services, New Drug Application, District court, Company, HBR, Infection, Food, Court, Jeanne Eagels, Complicated, News, Telephone, Treatment, Workforce, FDA, Patient, Urinary tract infection, Review, Tebipenem, NASDAQ, Population, Lists of schools in England, NDA, Degenerative disease, P.C, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Person, Pharmaceutical industry, Renewable energy, Spero, Pyelonephritis

Investors have until July 25, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until July 25, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Spero, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant bacterial infections and rare diseases in the United States.
  • The Company's product candidates include Tebipenem Pivoxil Hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults.
  • The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Companys business, operations, and prospects.

Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Spero Therapeutics, Inc. (SPRO)

Retrieved on: 
Wednesday, June 1, 2022
Legal, Professional Services, Steps, LCM, Spero, HBR, Company, Urinary tract infection, Population, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, News, Patient, NASDAQ, Review, Therapy, Infection, Degenerative disease, Failure, FDA, Workforce, Securities Exchange Act of 1934, MDR, NDA, Person, Pharmaceutical industry, Generic drug, Tebipenem

The Class: Shareholder rights law firm Robbins LLP informs investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Spero Therapeutics, Inc. (NASDAQ: SPRO) securities between October 28, 2021 and May 2, 2022.

Key Points: 
  • The Class: Shareholder rights law firm Robbins LLP informs investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Spero Therapeutics, Inc. (NASDAQ: SPRO) securities between October 28, 2021 and May 2, 2022.
  • Spero is clinical-stage biopharmaceutical company that focuses on developing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States.
  • The Company's product candidates include Tebipenem Pivoxil Hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

SPERO THERAPEUTICS, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Eastern District of New York against Spero Therapeutics, Inc

Retrieved on: 
Tuesday, May 31, 2022
HBR, Telephone, Company, Population, NEW, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, New Drug Application, News, Patient, Complicated, NASDAQ, Review, Therapy, Treatment, FDA, Workforce, Tebipenem, Lists of schools in England, Court, NDA, District court, GLOBE, Pharmaceutical industry, Renewable energy, Practice of law, Spero, Pyelonephritis

NEW YORK, May 31, 2022 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action lawsuit has been filed against Spero Therapeutics, Inc. (“Spero” or the Company“) (NASDAQ: SPRO) in the United States District Court for the Eastern District of New York on behalf of a class consisting of those that purchased or otherwise acquired Spero securities between October 28, 2021 and May 2, 2022,

Key Points: 
  • You may obtain additional information concerning the action or join the case on our website, www.whafh.com.
  • If you have incurred losses in Spero Therapeutics, Inc., you may, no later than July 25, 2022, request that the Court appoint you lead plaintiff of the proposed class.
  • The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Companys business, operations, and prospects.
  • On March 31, 2022, Spero issued a press release announcing the Companys fourth quarter and full year 2021 financial results.

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Spero Therapeutics, Inc. (SPRO)

Retrieved on: 
Tuesday, May 31, 2022
HBR, Company, Population, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, News, Patient, Complicated, NASDAQ, Review, Treatment, Complaint, FDA, Workforce, Tebipenem, NDA, District court, GLOBE, Pharmaceutical industry, Renewable energy, Spero, Pyelonephritis

On March 31, 2022, Spero issued a press release announcing the Companys fourth quarter and full year 2021 financial results.

Key Points: 
  • On March 31, 2022, Spero issued a press release announcing the Companys fourth quarter and full year 2021 financial results.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • If you wish to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq.
  • of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at [email protected] or [email protected] .